DNTH

Dianthus Therapeutics, Inc.

Healthcare
Biotechnology
$5.94B market cap

Forecast run · Sep 14, 2026Upside rank 632 of 3,136

Model Signal

ForecastQ Daily Probabilities

52.6%

33.3%

25.7%

Analyst Consensus

Recommendation1.91/5 Buy

Last price$106.20

Price target$126.83

Implied move+19.4%

Analysts11

ForecastQ Portfolios

DNTH is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.